



## Abivax late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021

September 28, 2021

**Principal investigator Prof. Séverine Vermeire, M.D., Ph.D, to present Abivax's late-breaking abstract on ABX464 phase 2b study results in ulcerative colitis (UC)  
October 4, 2021, at 10:42-10:54 am CEST**

**Abivax will also be hosting a Live Industry Symposium on ABX464's potential to address medical needs in UC, presentations will be given by key opinion leaders Prof. Bruce Sands, M.D., M.S. and Prof. William Sandborn, M.D.  
October 4, 2021, at 1:00-2:00 pm CEST**

**PARIS, France, September 28, 2021 – 6:00 pm (CEST) –** Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, would like to invite you to attend the Abivax late-breaking abstract presentation as well as the Abivax Live Industry Symposium at the UEG Week Virtual 2021 (registered UEG participants only). The UEG Week 2021 takes place virtually from October 3-5, 2021, and is one of the world's leading congresses focused on gastrointestinal diseases, such as Inflammatory Bowel Diseases (IBD).

### Abivax late-breaking abstract presentation

Abivax's [late-breaking abstract on its ABX464 phase 2b clinical data in UC](#) has been accepted for this year's UEG Week and will be presented by Prof. Séverine Vermeire, M.D., Ph.D, the principal investigator of the study. Participants will have the opportunity to ask questions after the presentation.

New data on Abivax's phase 2b maintenance results, including the first 101 patients who completed 48 weeks of daily treatment with ABX464, will be made public for the first time during the oral presentation.

**Abstract:** #AS-UEG-2021-02909

**Session:** Late-breaking Abstracts III: Clinical trials in IBD

**Talk:** Oral ABX464 QD is efficacious and safe during phase 2b induction and maintenance treatment of ulcerative colitis

**Time:** October 4, 2021 – at 10:42-10:54 am CEST (4:42-5:54 am EST)

**Presenter:** Prof. Séverine Vermeire, M.D., Ph.D., Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator of the ABX464 phase 2a and phase 2b clinical studies in UC

### Abivax Live Industry Symposium

The [symposium will be chaired by Prof. Bruce Sands, M.D., M.S.](#), of the Icahn School of Medicine at Mount Sinai, New York City, NY, USA. The focus of the symposium will be on the continued need for novel drugs in IBD, the clinical data from the phase 2b induction and maintenance studies with ABX464 in UC and the novel mechanism of action of ABX464.

Following the presentations, participants will have the opportunity to ask questions during the live Q&A session.

**Title:** ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis

**Time:** October 4, 2021 - 1:00-2:00 pm CEST (7:00-8:00 am EST)

- **The continued need to develop novel drugs for ulcerative colitis**

**Prof. William Sandborn, M.D.**

University of California San Diego School of Medicine and Co-Founder and Chief Medical Officer at Shoreline Biosciences, CA, USA

- **ABX464 novel mechanism of action: Upregulation of the anti-inflammatory microRNA miR-124**

**Program:**

**Didier Scherrer, Ph.D.**

Vice-President R&D, Abivax, France

- **Safety and efficacy of ABX464 in a phase 2b study in ulcerative colitis**

**Prof. Bruce Sands, M.D., M.S.**

Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York City, NY, USA

- **Live Q&A session**

Registered UEG Week participants can follow the live symposium and view the subsequently provided on-demand replay under the following link: <https://virtualweek.ueg.eu/symposium/is-10>

\*\*\*\*\*

**About Abivax ([www.abivax.com](http://www.abivax.com))**

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at [www.abivax.com](http://www.abivax.com). Follow us on Twitter @ABIVAX\_.

**Contacts**

**Abivax**

**Communications**

Regina Jehle

[regina.jehle@abivax.com](mailto:regina.jehle@abivax.com)

+33 6 24 50 69 63

**Investors**

**LifeSci Advisors**

Ligia Vela-Reid

[lvela-reid@lifesciadvisors.com](mailto:lvela-reid@lifesciadvisors.com)

+44 7413 825310

**Press Relations & Investors Europe**

**MC Services AG**

Anne Hennecke

[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

+49 211 529 252 22

**Public Relations France**

**Actifin**

Ghislaine Gasparetto

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

+33 6 21 10 49 24

**Public Relations France**

**DGM Conseil**

Thomas Roborel de Climens

[thomasdeclimens@dgm-conseil.fr](mailto:thomasdeclimens@dgm-conseil.fr)

+33 6 14 50 15 84

**Public Relations USA**

**Rooney Partners LLC**

Jeanene Timberlake

[jtimberlake@rooneypartners.com](mailto:jtimberlake@rooneypartners.com)

+1 646 770 8858